Drug Trial Radar · NCT01908725
Lamazym Aftercare Study
Last checked: Nov 20, 2026Latest source record: Jul 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Jun 2013
Primary completion
Sep 30, 2022
Study completion Sep 30, 2022
Sponsor
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Jul 26, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall objective of this trial is to provide aftercare treatment with Lamazym and to evaluate the safety of repeated Lamazym i.v. treatment of subjects with alpha-Mannosidosis whom previously participated in Lamazym-trial.
Conditions
- Alpha-Mannosidosis
Interventions
LamazymDrug
ERT, i.v. infusions weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Adverse eventsTime frame: 3 year
- Change from baseline in Lamazym antibodiesTime frame: 3 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9
Copenhagen, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.